175461-34-4

Basic information

• Product Name: (2,6-DICHLORO-PYRIDIN-4-YL)-DIMETHYL-AMINE
• Synonyms: (2,6-DICHLORO-PYRIDIN-4-YL)-DIMETHYL-AMINE;2,6-Dichloro-N,N-dimethylpyridin-4-amine
• CAS NO: 175461-34-4
• Molecular Formula: C₇H₈Cl₂N₂
• Molecular Weight: 191.05782
• Mol File: 175461-34-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (2,6-DICHLORO-PYRIDIN-4-YL)-DIMETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2,6-DICHLORO-PYRIDIN-4-YL)-DIMETHYL-AMINE(175461-34-4)
• EPA Substance Registry System: (2,6-DICHLORO-PYRIDIN-4-YL)-DIMETHYL-AMINE(175461-34-4)

Safety Data

• Hazardous Substances Data: 175461-34-4(Hazardous Substances Data)

Usage

General Description

(2,6-Dichloro-pyridin-4-yl)-dimethyl-amine is a chemical compound with the molecular formula C7H9Cl2N. It is a derivative of pyridine, which is a heterocyclic organic compound. This chemical is a dimethylamine salt of 2,6-dichloro-4-pyridinyl. It is used in the synthesis of pharmaceuticals and agrochemicals, and also as a building block in organic chemistry. The compound has potential biological and pharmacological activities and may be used as a tool compound for research purposes. Its precise applications and uses will depend on the specific research, pharmaceutical, or agrochemical needs.

Upstream product

• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 74-88-4 methyl iodide 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 16063-69-7 2,4,6-trichloropyridine 
• 506-59-2 N,N-dimethylammonium chloride 
• 98027-84-0 2,6-dichloro-4-iodopyridine 
• 2402-78-0 2,6-dichloropyridine 
• 124-40-3 dimethyl amine 

Relevant articles and documents

When Donors Turn into Acceptors: Ground and Excited State Properties of FeII Complexes with Amine-Substituted Tridentate Bis-imidazole-2-ylidene Pyridine Ligands

In search of new ligand motifs for photoactive iron(II) complexes with long-lived MLCT states, a series of six complexes with tridentate amine-functionalized bis-n-heterocyclic carbene (NHC)-pyridine ligands is presented. In the homoleptic complexes imidazole-, methylimidazole-, or benzimidazole-2-ylidene, NHC donors are employed in combination with pyridine, functionalized in the 4-position by dimethylamine or dibenzylamine. The effects of these different functionalities on the electronic structure of the complexes are examined through detailed ground state characterization by NMR, single crystal X-ray diffraction, as well as electrochemical and spectroscopic methods. The net influence of these different functionalities on orbital-orbital and electrostatic ligand-iron interactions is investigated thoroughly by density functional theory, and changes in the excited state behavior and lifetimes are finally examined by ultrafast optical spectroscopy. Great deviations of the initially expected effects by substitution in 4-position on the photochemical properties are observed, together with a significantly increased -acceptor interaction strength in the benzimidazole-2-ylidene functionalized complexes.

Stereo- and Regioselective Alkyne Hydrometallation with Gold(III) Hydrides

The hydroauration of internal and terminal alkynes by gold(III) hydride complexes [(C^N^C)AuH] was found to be mediated by radicals and proceeds by an unexpected binuclear outer-sphere mechanism to cleanly form trans-insertion products. Radical precursors such as azobisisobutyronitrile lead to a drastic rate enhancement. DFT calculations support the proposed radical mechanism, with very low activation barriers, and rule out mononuclear mechanistic alternatives. These alkyne hydroaurations are highly regio- and stereospecific for the formation of Z-vinyl isomers, with Z/E ratios of >99:1 in most cases.

COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).